Last reviewed · How we verify

Tarlige — Competitive Intelligence Brief

Tarlige (MIROGABALIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Voltage-dependent calcium channel subunit alpha-2/delta-1 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Tarlige (MIROGABALIN) — Daiichi Sankyo.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tarlige TARGET MIROGABALIN Daiichi Sankyo marketed Voltage-dependent calcium channel subunit alpha-2/delta-1
Horizant GABAPENTIN ENACARBIL Azurity marketed Anti-epileptic Agent Voltage-dependent calcium channel subunit alpha-2/delta-1 2011-01-01
Horizant Horizant University of Missouri-Columbia marketed Voltage-dependent calcium channel subunit alpha-2/delta-1, Voltage-dependent calcium channel subunit alpha-2/delta-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tarlige — Competitive Intelligence Brief. https://druglandscape.com/ci/mirogabalin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: